Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 147Melanoma 122Breast Neoplasms 98Squamous Cell Carcinoma of Head and Neck 96Triple Negative Breast Neoplasms 85Lung Neoplasms 64Neoplasm Metastasis 53Carcinoma, Renal Cell 49Neoplasms 46Head and Neck Neoplasms 46Colorectal Neoplasms 41Ovarian Neoplasms 38Carcinoma, Transitional Cell 36Carcinoma, Hepatocellular 36Pancreatic Neoplasms 35Urinary Bladder Neoplasms 34Recurrence 33Stomach Neoplasms 32Glioblastoma 30Brain Neoplasms 28Sarcoma 26Endometrial Neoplasms 25Prostatic Neoplasms 23Hodgkin Disease 22Uterine Cervical Neoplasms 19Fallopian Tube Neoplasms 19Carcinoma, Squamous Cell 19Esophageal Squamous Cell Carcinoma 17Adenocarcinoma 17Multiple Myeloma 16

Interventions

Magnetic Resonance Spectroscopy 2pembrolizumab 1naxitamab 1abemaciclib 1Vorinostat 1Tamoxifen 1Steroids 1Specimen Handling 1Letrozole 1Imatinib Mesylate 1Hormones 1Gemcitabine 1Cyclin-Dependent Kinase Inhibitor p18 1Cyclin-Dependent Kinase Inhibitor p16 1Capecitabine 1Biopsy 116-fluoroestradiol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Anatomic Stage IV Breast Cancer AJCC v8 × pembrolizumab × Clear all
NCT04190056 2023-08-31

Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer

University of California, San Francisco

Phase 2 Terminated
1 enrolled 4 charts
Breast

Anatomic Stage IV Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡